Antibiotic resistance of anaerobic bacteria of the Bacteroides fragilis group isolated in Europe
The June issue of Clinical Microbiology and Infectious Diseases published the results of a study on the antibiotic resistance of anaerobic bacteria of the group Bacteroides fragilis, isolated in Europe , conducted under the supervision of world-renowned Swedish microbiologist Karl-Erica Nord (C.-E. Nord).
The study involved 37 laboratories from 19 European countries. 1280 strains of anaerobic bacteria from the B.fragilis group were studied. For each of them, the biochemical characteristics were determined, as well as the sensitivity to modern anti-anerobic drugs (cefoxitin, clindamycin, moxifloxacin, imipenem, piperacillin / tazobactam and metronidazole) and the production of β-lactamases.
Among the strains studied, B.fragilis (65%), B.thetaiotaomicron (16%) and B.vulgatus (8% ) predominant other representatives of this group of anaerobic bacteria were much less common.
According to the results of the study, it was found that the vast majority of the anaerobic strains studied (96%) produced β-lactamases and 99% were resistant to ampicillin. The frequency of resistance to anti-anerobic drugs of different classes was: cefoxitin - 6%, clindamycin - 15%, moxifloxacin - 9%. The most active drugs against anaerobes were imipenem, piperacillin / tazobactam and metronidazole (less than 1% of resistant strains).
Comparing the data with the results of a similar study carried out in 1992, the sensitivity of bacteria of the B.fragilis group to anti-anaerobic drugs in Europe decreased. An increase in the frequency of resistance to all of the drugs studied was noted.
Currently, there is an increase in the resistance of various types of anaerobes to antibacterial preparations around the world, although the data obtained in different countries or regions can vary considerably. Therefore, there is an urgent need to continue multicenter studies of the sensitivity of anaerobic bacteria, in particular representatives of the B.fragilis group.